Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a hold rating to a buy rating in a research report report published on Thursday. The firm currently has $4.25 price target on the stock.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
Several other brokerages have also recently issued reports on NH. Jefferies Group reiterated a buy rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. Canaccord Genuity dropped their target price on shares of NantHealth from $6.00 to $5.00 and set a buy rating on the stock in a report on Friday, November 17th. Finally, BidaskClub cut shares of NantHealth from a sell rating to a strong sell rating in a report on Wednesday, December 6th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $8.05.
NantHealth (NASDAQ:NH) last issued its earnings results on Thursday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative net margin of 225.76% and a negative return on equity of 46.09%. The company had revenue of $21.76 million for the quarter, compared to analysts’ expectations of $29.42 million. During the same period in the prior year, the business earned ($0.18) EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. research analysts predict that NantHealth will post -1.35 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP grew its holdings in NantHealth by 154.7% during the 3rd quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock worth $299,000 after acquiring an additional 44,100 shares in the last quarter. Highbridge Capital Management LLC boosted its holdings in shares of NantHealth by 6.5% in the 3rd quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock valued at $1,030,000 after buying an additional 15,264 shares in the last quarter. National Planning Corp boosted its holdings in shares of NantHealth by 21.1% in the 3rd quarter. National Planning Corp now owns 138,700 shares of the company’s stock valued at $656,000 after buying an additional 24,200 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of NantHealth in the 3rd quarter valued at about $365,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of NantHealth in the 3rd quarter valued at about $180,000. Institutional investors own 7.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2018/01/15/nanthealth-nh-stock-rating-upgraded-by-zacks-investment-research.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about NantHealth? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NantHealth and related companies.